OBJECTIVE To comprehensively describe patient-reported, functional and neurophysiological outcomes to elucidate the phenotypic profile of taxane-induced neuropathy. METHODS Taxane-treated patients (n = 47) completed cross-sectional bilateral clinical and sensory assessments and nerve conduction studies. Patients reported symptom severity via Functional Assessment of Cancer Therapy/Gynecologic Oncology Group-Neurotoxicity (FACT/GOG-Ntx13) questionnaire. RESULTS Symptoms of neuropathy were reported by 81% of patients. On clinical examination, 62% had 2 or more abnormalities, with 20% indicating significant symptomatic and objective neuropathy. Nerve conduction studies were consistent with a sensory predominant axonal neuropathy. However, features more typical of entrapment neuropathy were also present in > 50%, which were not associated with overall severity of chemotherapy-induced peripheral neuropathy (CIPN) or clinical risk factors. CONCLUSIONS There is considerable variation in CIPN phenotypes associated with taxane-treatment. Understanding their clinical associations may assist in identification of patients at risk of severe neurotoxicity. This would enable treatment modification decisions but also limit early cessation of effective anti-cancer treatment in patients with less severe neurological sequelae. SIGNIFICANCE Understanding the CIPN phenotype may inform treatment decisions which could impact clinical and survival outcomes.

中文翻译：

---

紫杉烷诱导的神经病变的电生理和表型特征

目的 全面描述患者报告的功能和神经生理学结果，以阐明紫杉烷诱导的神经病变的表型特征。方法紫杉烷治疗的患者（n = 47）完成了横断面双侧临床和感觉评估以及神经传导研究。患者通过癌症治疗功能评估/妇科肿瘤组 - 神经毒性 (FACT/GOG-Ntx13) 问卷报告症状严重程度。结果 81% 的患者报告了神经病变的症状。在临床检查中，62% 有 2 个或更多异常，20% 表明有明显的症状和客观神经病变。神经传导研究符合感觉为主的轴突神经病。然而，超过 50% 的患者也存在更典型的卡压性神经病特征，这与化疗引起的周围神经病变 (CIPN) 的总体严重程度或临床危险因素无关。结论 与紫杉烷治疗相关的 CIPN 表型存在相当大的差异。了解它们的临床关联可能有助于识别有严重神经毒性风险的患者。这将使治疗修改决策成为可能，但也限制了神经系统后遗症不太严重的患者早期停止有效抗癌治疗。意义 了解 CIPN 表型可为治疗决策提供信息，从而影响临床和生存结果。了解它们的临床关联可能有助于识别有严重神经毒性风险的患者。这将使治疗修改决策成为可能，但也限制了神经系统后遗症不太严重的患者早期停止有效抗癌治疗。意义 了解 CIPN 表型可为治疗决策提供信息，从而影响临床和生存结果。了解它们的临床关联可能有助于识别有严重神经毒性风险的患者。这将使治疗修改决策成为可能，但也限制了神经系统后遗症不太严重的患者早期停止有效抗癌治疗。意义 了解 CIPN 表型可为治疗决策提供信息，从而影响临床和生存结果。